Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
CardioNerds (Dr. Apoorva Gangavelli, Dr. Cory Sejo, and Dr. Joseph Kassab), discuss tricuspid regurgitation evaluation and management with Dr. Sunil Mankad. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course. Audio editing by CardioNerds intern Emma Winakur. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Key Points: Tricuspid regurgitation is common and associated with increased mortality at every stage, regardless of etiology. Outcomes are worse with worsening severity, so accurate grading is critical. Etiology is critical to guide treatment decisions. Etiology includes primary vs secondary (atrial or ventricular) vs CIED-related TR. 3D echocardiography can be very helpful in determining TR etiology, especially in CIED-related TR. Diuresis with the goal of euvolemia is step one. Additionally, underlying contributory conditions (eg. pulmonary HTN, HFrEF, atrial fibrillation) should be addressed, if appropriate, and then TR severity reassessed. The choice between T-TEER and TTVR hinges on anatomy, RV function, pulmonary hypertension, and the ability to tolerate anticoagulation. T-TEER is generally first line in atrial functional TR with appropriate anatomy, in patients with poor RV function who cannot tolerate a sudden increase in RV afterload, or in patients who cannot tolerate the necessary anticoagulation with TTVR. TTVR is preferred with wide coaptation gaps and CIED-related TR. This is a team sport. Multidisciplinary discussions utilizing imaging (TTE/TEE, CT), risk scores (TRI-SCORE or TRIO), patient preference, and prior institutional experience are essential for the effective treatment of severe TR. Notes: What is the clinical importance of tricuspid regurgitation? TR is very common with approximately 4% of people over 75 having moderate or greater severity. TR (even mild) is associated with increased mortality. Those outcomes worsen as the TR severity worsens, and this phenomenon is independent of the mechanism of regurgitation. What is unique about the tricuspid valve compared to the other cardiac valves? It is at an anterior location which allows it to be imaged well with transthoracic echocardiography It is the largest valve and composed generally of 3 leaflets (but very often can have 4+ leaflets). Importantly, the RV is compliant and changes size and shape readily based on loading conditions. The TV annulus similarly changes size and shape based on hemodynamic conditions such as preload. What is a good framework for approaching the causes of tricuspid regurgitation? Determine the presence and define the severity of TR. Using TTE, we want to measure the right atrial size, the RV size, and any other concomitant valvular lesions. Use TTE (2D and 3D) to characterize leaflet anatomy and characteristics. Subtypes of TR mechanisms (many times etiology is mixed). Primary: primary leaflet abnormality, occurs in ~10% of cases. Look for prolapse, flail, endocarditis, etc. Secondary/functional: leaflets normal but surrounding structures are abnormal. Atrial: RA and tricuspid annular dilation but normal RV size/shape, and can be related to arrhythmias like atrial fibrillation. Ventricular: RV dilated and/or dysfunctional with leaflet tethering. Can be related to pulmonary hypertension or primary RV disease. Cardiac implantable electronic device (CIED): Related to device (usually pacemakers or ICD) interaction with TV leaflets. Includes perforation, entanglement in subvalvular apparatus, impingement, etc. 3D TTE particularly helpful to evaluate How do we grade TR severity? It is very important to grade the severity of TR, and this is generally done with echocardiography. There are both quantitative and qualitative methods which use Doppler and various equations to estimate TR severity. Current recommendations have expanded TR severity beyond mild/moderate/severe to include “massive” and “torrential” categories. The most important parameters measured/calculated are vena contracta width, regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. Helpful qualitative metrics include hepatic venous flow reversal. When should additional studies beyond transthoracic echocardiography, such as transesophageal echocardiography (TEE), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI) be pursued? TEE is particularly helpful if TTE views are poor. Since TEE is used during transcatheter intervention, a pre-procedure TEE to define anatomy, determine procedure candidacy, and plan for the procedure is critical. CT is also helpful for procedure planning and has particular strengths in defining annulus size and geometry. A CT is required prior to transcatheter tricuspid valve replacement (TTVR). MRI is helpful for measuring RV volumes and function, but is not generally used to assess TR severity. What is the approach to the treatment for severe tricuspid regurgitation? The first step is to try to determine the etiology. For secondary TR, treating the underlying condition is indicated. For example, pulmonary vasodilators for pulmonary HTN or guideline therapy for heart failure with reduced ejection fraction. Diuretics are the mainstay for treatment, with the goal to obtain euvolemia. This may require inpatient admission to optimize volume status and medication regimen. Once reversible etiologies are addressed, if the patient is still symptomatic from TR, additional therapies can be considered. What is the role of right heart catheterizations (RHC) in patients with severe TR? RHC is very helpful for many reasons. We use it in TR to help determine volume status, cardiac output, and RV function. Additionally, identifying and characterizing pulmonary hypertension (with pulmonary artery pressures and calculating pulmonary vascular resistance) is an important factor when choosing future therapies. With severe tricuspid regurgitation, when should we refer for intervention (either with surgery or transcatheter repair or replacement)? Once reversible etiologies are addressed and euvolemia has been achieved, if the patient is still symptomatic from TR despite aggressive medical optimization, additional therapies can be considered. Once euvolemic, a repeat TTE should be ordered to reassess the severity of the TR. Use calculators (for example, either the TRI-SCORE or TRIO score) to predict operative mortality for isolated TR surgery. What are our transcatheter treatment options in severe tricuspid regurgitation, and how do we choose between them? The primary approved transcatheter treatment options for severe TR include transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), of which the Edwards EVOQUE valve is the only one currently approved by the FDA. There are other TTVR device under investigation. These decisions should be made with a multi-disciplinary team including representation from cardiac imaging, interventional cardiology, and cardiothoracic surgery. Factors that go into the decision between T-TEER and TTVR include anatomy (annulus width, coaptation gap, leaflet length), RV reserve, pulmonary hypertension presence, ability to tolerate anticoagulation, patient preference, and institutional experience. T-TEER is generally the first line with atrial functional and suitable anatomy. It is successful at reducing TR but does not generally eliminate it. TTVR with EVOQUE is preferred in certain anatomic considerations like a large coaptation gap or when there is CIED-related TR (as this was excluded in T-TEER trials). Patients must be suitable for anticoagulation to receive TTVR as there is risk of leaflet thrombosis without it. If moderate/severe pulmonary hypertension is present, or there is poor RV function, TTVR may be avoided as the sudden elimination of TR causes a sudden increase in RV afterload which may not be tolerated. What is the role in advanced metrics for evaluating RV function? Advanced metrics like RV/PA coupling are under investigation but have not made it into the guidelines. The clinical utility is not yet known. Assessing the RV function is important as stated above. Dr. Mankad prefers using 3D TTE to calculate an RVEF, or tracking RV longitudinal free wall strain. If you do encounter CIED-related TR, how do you treat it? Evaluate with TTE or TEE. 3D is very helpful to identify relative anatomy and leaflet-device interactions. There is no clear consensus about treatment if CIED-related TR is the primary mechanism of severe TR. If recently implanted, repositioning may be a valid option, but requires discussions with multiple teams including electrophysiology, advanced cardiac imaging, CT surgery, and interventional cardiology. References O’Gara PT, Lindenfeld J, Hahn RT, et al. 10 Issues for the Clinician in Tricuspid Regurgitation Evaluation and Management: 2025 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2025;S0735-1097(25)07047-0. O’Gara PT, Little SH, Badhwar V, et al. Operator and Institutional Recommendations and Requirements for Tricuspid Interventions: 2026 ACC/AHA/ASE/HRS/STS Expert Consensus Systems of Care Document. J Am Coll Cardiol. 2026;S0735-1097(26)05481-1. Hahn RT. Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876-1891. Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149(22):e1223-e1238.
Guest: Jerold MandeShow Notes:What if improving health means not just having enough food—but having access to the right kinds of food? This episode explores how nutrition security, public policy, and healthcare systems work together to shape diet quality and chronic disease prevention—and what it will take to build a healthier future.Guest Bio:Jerold Mande is CEO of Nourish Science; Adjunct Professor of Nutrition, Harvard T.H. Chan School of Public Health; and a Non-Resident Senior Fellow, Tisch College of Civic Life, Tufts University. For most of his career, he has served in senior federal food, nutrition, and health policy positions, including the FDA and USDA. Quote:"Food security just means people have access to food, but it doesn't mean they have access to food that they'll thrive on."Question of the Day:What changes, whether in policy or your local community—would make it easier for people to access nutritious food where you live?On This Episode You Will Learn:The difference between food security and nutrition security, and why both matter for preventing chronic disease.How government policies and food programs influence the foods we see in grocery stores, schools, and communities.Why ultra-processed foods have become such a big part of the American diet and how they may affect our health.The story behind the Nutrition Facts label and MyPlate, and how they changed the way Americans think about nutrition.What changes in food policy and nutrition research could help create a healthier future for everyone.Connect with Yumlish!Yumlish Website: YumlishYumlish on Instagram: @yumlish_Yumlish on Facebook: YumlishYumlish on Twitter: @yumlish_Yumlish on LinkedIn: YumlishConnect with Jerold Mande!Website URL: https://nourishscience.org/ https://hsph.harvard.edu/profile/jerold-r-mande/Twitter(X) URL: @JerryMandeLinkedIn URL: www.linkedin.com/in/jerold-mande
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show
Most companies bring in regulatory expertise when they're ready to file. Leland Keyt, VP of Regulatory Affairs and Quality Assurance at Apreo Health, makes the case that by then you've already absorbed costs you didn't need to, and explains what early regulatory partnership actually looks like in practice.Leland and Nick get into why risk tolerance is the thing that catches scaling companies, the hidden costs of rework beyond timeline, how regulatory input changes product decisions across geographies, and what regulators are scrutinizing more closely now.A few of Leland's key takeaways:Early means concept phase, not pre-submission. Even your IP narrative can matter years later in a submissionCompanies often run more testing than they need. Efficiency means answering the right questions with the least dataRisk tolerance is what gets companies in trouble. What's acceptable in development isn't acceptable at PMAPost-market obligations happen underneath the water, and they're a resourcing problem more than a regulatory oneRework isn't just timeline, it's product cost and a supply chain issueBiocompatibility interpretation varies by geography and can change what you develop and whenAI, usability, and management review are all getting closer regulatory attentionBuild a scalable QMS. It's the bedrock, and it isn't an afterthoughtAbout Leland KeytLeland Keyt is VP of Regulatory Affairs and Quality Assurance at Apreo Health, which is running a US pivotal study for an implantable airway scaffold for severe emphysema. She has over 20 years in medical devices across startups, mid-size companies, and multinationals, previously serving as Chief Product Officer at Biorithm and Senior Director of RA/QA at Pulmonx, where she navigated FDA's Breakthrough Device Program to a 178-day PMA approval.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/
President Trump signed an executive order updating recommended childhood immunizations—reducing the core schedule from 18 vaccines down to protections against 11 diseases, spacing out doses, and recommending single-dose MMR options. While medical and scientific consensus maintains there is no link between vaccines and autism, both the President and Health and Human Services Secretary Robert F. Kennedy Jr. suggested at the signing that a link may exist between the expanded schedule and rising autism rates. Dr. Stephanie Haridopolos from the Department of Health and Human Services (HHS) joins the Rundown to examine what this new guidance actually changes. She discusses HHS's approach to vaccine safety research, efforts to rebuild public trust, pediatric recommendations, and the administration's plan to investigate potential environmental triggers behind brain inflammation and autism.The restaurant industry is navigating complex challenges in food safety as recent FDA investigations into widespread foodborne outbreaks leave consumers on edge. Chef and restaurateur David Burke joins to discuss how his 18 locations manage major supply recalls through centralized buying, the pros and cons of local sourcing versus large distributors, and practical advice for consumers navigating food safety concerns when dining out. PLUS, commentary by Jason Chaffetz, FOX News contributor and the host of the Jason In The House podcast on FOX News Radio. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Urge urinary incontinence (UUI) places a significant emotional and physical burden on women affected. Sacral neuromodulation has been and remains a well-established implant-based therapy for UUI. The concept originated in the early 1970s from sacral anterior root stimulation research for neurogenic bladder, with human clinical trials beginning in 1982. Medtronic's InterStim device received FDA approval in 1997 for UUI, and in 1999 for urgency-frequency and nonobstructive urinary retention. This was a game changer for affected women. Now, as of August 5, 2026, the FDA has granted 510(k) clearance for a new, less invasive neuromodulation implant- placed in the ANKLE. This is the Revi Extend Implant system (BlueWind Medical). What was the phase 3 data on this? What does the “wearable controller device” look like? Listen in for details. 1. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAMA. 2017;318(16):1592–1604. doi:10.1001/jama.2017.121372. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-year efficacy and safety of Revi implantable tibial neuromodulation from the pivotal OASIS study. J Urol. 2026;216(2):219-229. doi:10.1097/JU.00000000000050623. BlueWind Medical receives FDA 510(k) clearance for Revi Extend implant. News release. BlueWind Medical Ltd. August 5, 2026. Accessed August 5, 2026. https://www.businesswire.com/news/home/20260805290667/en/BlueWind-Medical-Receives-FDA-510k-Clearance-for-Revi-Extend-Implant
On this episode of Vitality Radio, Jared continues his Topical Medicine Cabinet series with the products he reaches for most to apply topically for healthy skin, skin comfort, and everyday first aid. He explains why nano silver gel has become his go-to for everything from post-shaving care and natural deodorant to supporting the skin's natural healing process after minor burns and blemishes. He also explores the benefits of whipped beef tallow, herbal balms featuring traditionally used botanicals like comfrey and calendula, natural options for itchy skin, and topical essential oil blends for occasional tension headaches. Along the way, Jared breaks down the science, traditional herbal wisdom, and practical ways to build a natural topical medicine cabinet for the whole family.Products:Vitality Nutrition Nano-Silver Skin GelAtrubein Whipped Dream Beef Tallow Body CreamRoots & Leaves Whipped Tallow BalmGolden Age Naturals Tallow BalmAuminay Itch-Away BalmAuminay Herbal BalmQuantum Lysine OintmentQuantum Lysine Lip BalmAuminay Tension TamerAdditional Information:663: Topical Medicine Cabinet - Part 1: Pain, Injury & Muscle Recovery Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.comhttps://drtalks.com/podcast-service/
Send us Fan MailProbiotics left US NICUs after the FDA reclassified them, and NEC rates went up. This week Ben reviews the Connection Study, a 2,158 infant phase 3 trial of IBP-9414, a live biotherapeutic product containing Limosilactobacillus reuteri, run under an IND with the regulatory rigor probiotics never had. Neither primary endpoint reached significance, but all cause mortality fell 27%, and surgically confirmed NEC favored treatment after 14 days of dosing. The discussion may be the real story, including a kappa of 0.36 between radiologists reading the same NEC films. Ben and Daphna talk through what a regulated probiotic would mean for the babies waiting now.----Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. Neu J, Del Moral T, Guthrie SO, Hudak ML, Indrio F, Kim JH, Kronström A, Martin CR, Modi N, Rastad J, Schnitzer TJ, Singh R, Strömberg S, Szajewska H, Thuresson M, Caplan M.Pediatr Res. 2026 Feb 20. doi: 10.1038/s41390-026-04826-7. Online ahead of print.PMID: 41721054Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!
A blistering, high-energy breakdown uncovering newly highlighted disclosures, private text chains, and leaked audio surrounding COVID-19 vaccine policy and censorship! The discussion dives deep into the upcoming FDA-approved mRNA flu vaccine, exposing critical safety data hidden behind study paywalls and warning listeners about potential risks. Plus, updates on immigration deportation records, Florida's potential legal actions, and the ongoing fight for medical transparency!
What happens when someone who volunteered for a COVID-19 vaccine clinical trial says the shot changed her life within hours? On this episode of The Tudor Dixon Podcast, Tudor sits down with Brianne Dressen, co-founder of React19 and a participant in the AstraZeneca COVID-19 vaccine clinical trial, to discuss her experience with what she describes as a severe and lasting vaccine injury. Dressen recounts developing neurological symptoms shortly after receiving the shot, including burning and tingling, numbness, difficulty walking, sensitivity to light and sound, vision problems, and cognitive issues. She says some symptoms remain with her nearly six years later. She also describes receiving treatment at the National Institutes of Health, saying the intervention produced a significant improvement but that she has continued to require treatment. Tudor and Dressen discuss informed consent during vaccine trials, the treatment of people reporting adverse events, Anthony Fauci and the NIH, pharmaceutical-company accountability, and Dressen's allegations that officials knew more about certain adverse effects than was publicly acknowledged. Dressen also explains why she believes further federal investigation is necessary. It’s a wide-ranging conversation about one woman's experience, unanswered questions from the COVID era, and the continuing debate over transparency, medical treatment, and accountability. Subscribe to The Tudor Dixon Podcast on iHeartRadio, Apple Podcasts, YouTube, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.
Are PPOs quietly costing your dental practice hundreds of thousands of dollars? In this episode, PPO expert Shelley DeGroff reveals how hidden contract terms, outdated reimbursement rates, and insurance strategies can significantly reduce profitability without most dentists even realizing it.Host Art Wiederman sits down with Shelley DeGroff, founder of PPO Advisors, to unpack the complex world of PPO insurance and explain why understanding your contracts is one of the fastest ways to improve your practice's financial health. Shelley shares how insurance companies use data mining to monitor practices, why dentists should regularly negotiate reimbursement rates, and how many providers unknowingly accept lower payments because they are contracted through multiple hidden network agreements.The conversation also explores common mistakes that can expose practices to compliance risks, including improper patient discounts and NPI credentialing fraud during practice transitions. Shelley explains why these issues are more serious than many dentists realize and offers practical guidance for avoiding costly mistakes. The episode concludes with advice on evaluating whether to stay in network or transition out of network, emphasizing that the right strategy depends on your practice goals, patient relationships, and long term profitability. Dentists will leave with a better understanding of how to take control of their insurance participation instead of letting insurance companies dictate the future of their practice.Connect with Shelley!
News: After Aid Cuts, US Announces $2 Billion for Christian Groups @1:22 Greenland issues ‘strong warning' as Trump-linked oil firm prepares to drill @2:48 Politics: Religious Liberty Commission lawsuit dismissed @5:38 Dan Patrick directs Texas Senate to study ways to further religion @8:54 Lt. Gov. Beckwith wants Indiana candidates to attest belief @10:17 Trump hid in catering truck in secret plane swap over Iran threat @12:21 Max Miller tangent @17:55 Trump-backed candidate Amir Hasaan in Michigan loses @19:25 Health/Medicine/Science: Trump signs executive order on childhood vaccine recommendations @23:50 Report: Trump mad RFK Jr. hasn't cut more vaccines or proven autism link @25:06 Stop 'Harassment' of Fauci, Scientists Urge Politicians @26:39 Dr. Anthony Fauci repeatedly invokes the Fifth in Senate hearing Ripple Effect Why? Anecdote Dinosaur soft tissue @32:16 Circumcision and Autism: What a New Study Found @37:35 The Peptide Wild West @40:24 Maharashtra allows homeopaths to prescribe allopathic medicines @44:12 Good news Moderna's mRNA flu shot earns FDA approval after rollercoaster review @46:20 Austin ISD vaccination rates surpass 95% after sharp rebound @47:11 Religious Nonsense: Young Latinos abandoning churches to be "nones" @48:01 Final Stories: Posts claim Earth will 'lose gravity' for 7 seconds on Aug. 12, 2026 @49:03
The National Drug Code (NDC) is a critical identifier used throughout the healthcare supply chain, supporting product identification across manufacturers, distributors, pharmacies, providers, payers, and data systems. In this episode, Reid Jackson and Liz Sertl chat with Ullrich Mayeski, Community Engagement Director - Healthcare at GS1 US. He explains the FDA's transition from the current 10-digit NDC format to a 12-digit format planned for 2033. Ullrich discusses why the change is happening, how the update will affect healthcare organizations, and why businesses should begin reviewing the systems, processes, and trading partner connections that rely on NDC data. The conversation explores the move toward a consistent NDC structure, the role of 2D barcodes, and how better product identification can support traceability, data exchange, and patient safety throughout the healthcare supply chain. In this episode, you'll learn: Why the NDC transition from 10 digits to 12 digits is reshaping healthcare product identification The biggest challenges manufacturers, distributors, pharmacies, and providers face as they prepare for the 2033 change How standardized data and 2D barcodes can improve product information, traceability, and supply chain communication Things to listen for: (00:00) Introducing Next Level Supply Chain (02:11) Ullrich's role supporting healthcare organizations at GS1 US (03:54) Why the National Drug Code is a critical healthcare identifier (06:24) Why the NDC format is changing from 10 digits to 12 digits (08:23) How the new format supports greater consistency across systems (10:49) Why the transition affects more than pharmaceutical manufacturers (13:32) The systems and processes organizations need to evaluate (17:27) How over-the-counter products are also affected (19:19) Why organizations should begin preparing now (23:36) How the NDC transition connects to traceability and 2D barcode adoption (26:21) How better data capture can support patient safety Connect with GS1 US: Our website - www.gs1us.orgGS1 US on LinkedIn Connect with the guest: Ullrich Mayeski on LinkedIn
Send us Fan MailStella Fosse was a teenager when she determined to publish her first book by the age of 25. That didn't happen. She published her first book at 68. And it was very different from her early aspirations.Join host Jane Trombley in conversation with Stella, a former Biotech writer who pivoted to “elderotica” — in both nonfiction and as a thread throughout her novels. During a 25-year career as a tech writer, Stella focused on writing, submitting applications, and gaining FDA approval for Biotech products. Along the way, she joined a group of women authors reading their erotic essays featuring powerful female central characters. Stella began to dabble in the genre, participating in writing and reading her work, what she called “elderotica.” It was time to pivot. With little more than an idea for a guide for midlife women exploring erotica, Stella published her first book, Aphrodite's Pen: The Power of Writing Erotica After Midlife. It would come as no surprise that the launch party for Aphrodite's Pen was held at a sex toy shop in Berkeley, CA. The rest, as they say, is publishing history. Stella shows us the power of the pivot and a commitment to advocating for women's creativity, often emerging in midlife and beyond. Come join the conversation.Show Notes:Website: www.stellafosse.comSubstack: stellafosse.substack.comGrandmother Collective on SubstackCrone HubStella's BooksRock On: Power, Sex and Money after 60Write & Sell a Well-Seasoned Romance:Launch Your Author Adventure in Late-Life RomanceVampires of a Certain Age:Five Hundred Years of LovingBrilliant Charming Bastard:Getting Rich is the Best RevengeThe Erotic Pandemic Ball: Tales of Love in LockdownAphrodite's Pen: The Power of Writing Erotica After MidlifeMentioned in the episode:Joan PriceRuth SaxtonSibylline PressSupport the show
President Trump signed an executive order updating recommended childhood immunizations—reducing the core schedule from 18 vaccines down to protections against 11 diseases, spacing out doses, and recommending single-dose MMR options. While medical and scientific consensus maintains there is no link between vaccines and autism, both the President and Health and Human Services Secretary Robert F. Kennedy Jr. suggested at the signing that a link may exist between the expanded schedule and rising autism rates. Dr. Stephanie Haridopolos from the Department of Health and Human Services (HHS) joins the Rundown to examine what this new guidance actually changes. She discusses HHS's approach to vaccine safety research, efforts to rebuild public trust, pediatric recommendations, and the administration's plan to investigate potential environmental triggers behind brain inflammation and autism.The restaurant industry is navigating complex challenges in food safety as recent FDA investigations into widespread foodborne outbreaks leave consumers on edge. Chef and restaurateur David Burke joins to discuss how his 18 locations manage major supply recalls through centralized buying, the pros and cons of local sourcing versus large distributors, and practical advice for consumers navigating food safety concerns when dining out. PLUS, commentary by Jason Chaffetz, FOX News contributor and the host of the Jason In The House podcast on FOX News Radio. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation. Bristol Myers Squibb has made headlines with its substantial $2.3 billion investment in a new manufacturing campus in Houston. This strategic move aims to significantly bolster their capabilities across various modalities including small molecules, biologics, and antibody-drug conjugates. The establishment of this facility is a testament to the growing demand for advanced manufacturing infrastructure needed to support complex therapeutics production. As BMS strengthens its operational capacity, it positions itself to better meet the increasing global demand for innovative treatments. In parallel developments, Jazz Pharmaceuticals is expanding its rare epilepsy pipeline through a $1.3 billion acquisition of Actio Biosciences. This strategic acquisition aligns with Jazz's focus on rare diseases with significant unmet medical needs. By integrating Actio's novel small molecule approach, Jazz aims to leverage these innovative therapies to improve patient outcomes in the rare epilepsy market, highlighting a critical shift towards targeted treatments. Vaderis Therapeutics has successfully raised $152 million in Series B funding, aimed at advancing its AKT-targeting treatment for hereditary hemorrhagic telangiectasia (HHT). This funding will support clinical development efforts, offering hope for patients with this rare vascular disorder who currently have limited therapeutic options. The advancement of such targeted therapies underscores the growing focus on addressing rare diseases within the biotech sector. Clinical trial advancements remain pivotal, with MoonLake Immunotherapeutics reporting positive Phase 3 data for sonelokimab, an IL-17A/F inhibitor targeting psoriatic arthritis. This nanobody-based antibody offers a novel mechanism of action by modulating autoimmune pathways involved in psoriatic arthritis, demonstrating the potential of biologics in managing complex autoimmune conditions. In a transformative approach to drug discovery, Aureka Biotechnologies has raised $100 million in Series B funding to further its platform-enabled efforts in antibody and protein design using AI and machine learning technologies. This integration represents a significant step forward, enhancing efficiency and precision in identifying viable therapeutic candidates. Despite these advancements, regulatory challenges persist. The FDA recently rejected ITM Isotope Technologies' application for 177Lu-edotreotide due to manufacturing concerns related to gastroenteropancreatic neuroendocrine tumors. Such setbacks underscore the critical importance of robust manufacturing practices and regulatory compliance to ensure patient safety and product efficacy. BridgeBio and Alnylam Pharmaceuticals are engaged in a competitive race targeting first-line ATTR-CM patients with differing therapeutic approaches—“silencer” versus “stabilizer” therapies. This debate highlights the intricacies involved in treating transthyretin amyloidosis (ATTR), a condition affecting the heart and nervous system, pointing towards potential breakthrough treatments that could significantly improve patient outcomes. On the regulatory front, President Donald Trump has signed an executive order aimed at revising pediatric vaccine recommendations, reflecting a shift in public health policy that could affect vaccination rates and parental decision-making regarding childhood immunizations. WuXi AppTec recently secured a temporary victory in its legal battle with the U.S. Department of Defense regarding its classification as a Chinese military company. This case highlights the geopolitical complexities faced by global pharmaceutical companies operating in sensitive markets. Meanwhile, technological innovation continues to shape healthcare delivery, exemplified by Abbott's partnership with Google Health to develop an AI-powered health insights application. This collaboration is part of a growing trend toward integrating digital technologies into healthcare to enhance diagnostics and personalized medicine. Finally, strategic corporate restructuring is evident as Aura Biosciences refocuses its R&D efforts on ocular oncology under new leadership. Such moves reflect broader trends within biotech firms to streamline operations and concentrate resources on high-potential therapeutic areas. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific innovation, strategic alliances, regulatory shifts, and technological integration—all aimed at advancing patient care and therapeutic efficacy in an increasingly complex global environment. As companies continue to navigate these challenges and opportunities, they are set to reshape the future of drug development with significant implications for patient outcomes worldwide.Support the show
Como os novos avanços da terapia radioligante, os desafios da comunicação científica na era digital e o foco no impacto clínico da IA transformam a prática médica? Neste episódio do Afya News, analisamos a decisão da FDA que ampliou o uso do Pluvicto (lutécio Lu-177) para estágios mais precoces do câncer de próstata metastático sensível à modulação hormonal, destacando a importância da seleção por PET-PSMA e do trabalho multidisciplinar. Discutimos também o artigo publicado na Nature Medicine pela Quality Health Information for All Commission sobre a necessidade de combater a desinformação para aprimorar a relação médico-paciente. Por fim, apresentamos no Radar o debate da American Medical Association com lideranças médicas abordando a integração segura e responsável da inteligência artificial nos fluxos de trabalho. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/12-08-2026Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.
Para precio y disponibilidad, vaya a este vínculo: https://amzn.to/4welLOV En este episodio Otto presenta unos audífonos de Anker que cancelan ronquidos y generan ruido blanco para dormir mejor, comparte su experiencia personal y dónde encontrar más detalles en sus redes. También conversan sobre agentes de inteligencia artificial que organizan viajes, reservan en gimnasios o gestionan turnos —y los problemas éticos y fallos que han permitido a usuarios manipular listas—, así como el impacto de estas herramientas en la vida diaria. Además, hablan del próximo iPhone 18, posibles colores y el nuevo programa de leasing de Apple, y de la aprobación por la FDA de audífonos de Samsung que ayudan a personas con problemas de audición a un costo más accesible. WWW.OTTOTECNOLOGIA.COM .
Anthony Fauci went to medical school, but never practiced medicine. Instead he moved to the dark side, where he became a bureaucrat's bureaucrat in an agency that Congress had no proper authority to create. In doing so, he lined his pocket - and his friends' pockets - with your tax money while killing millions.
Trevor Ault has the latest on the devastating 7.4 magnitude earthquake that rocked Colombia – collapsing buildings, trapping people under rubble and killing over 100 people; Mary Bruce reports on the executive order Pres. Trump signed to limit childhood vaccines, calling for children to get vaccinated against 11 diseases instead of the 18 previously recommended by the CDC; Elizabeth Schulze has details on some of the country's biggest grocery stores recalling dozens of products with jalapeños over fears of a growing salmonella outbreak, which the FDA says has sickened 345 people across 27 states; and more on tonight's broadcast of World News Tonight with David Muir. Learn more about your ad choices. Visit podcastchoices.com/adchoices
────────────────────────────────────────[00:02:07]Partisan Split Attempt on Flock and Data Centers — Don't Abandon This Bipartisan Issue to the LeftNew York Sun calls it a leftist crusade; Politico frames it as a radical Democrat movement; if you oppose these because Democrats oppose them, you are serving the surveillance state.────────────────────────────────────────[00:22:37]Tyler Hudson Essay: "I Cannot Remember a Single Child Who Couldn't Speak" — Now It's One in 20 BoysA 22-year autism dad documents childhood in the 1970s; nobody he asks remembers a single nonverbal child; autism was one in 10,000 in 1983, now one in 20 among boys.────────────────────────────────────────[00:32:21]New Cholesterol Guidelines Would Make 100 Million Americans Patients — Disease Creation for a Drug MarketAHA lowered the LDL threshold to 100; a third of Americans now technically diseased; new drugs are ready; purpose is to create lifelong customers.────────────────────────────────────────[00:34:25]Trump's Childhood Vaccine Executive Order Is a Head Fake — States Set the Schedule, Not the PresidentHe signed an order to limit vaccines and split the MMR; states control the schedule; FDA just approved a new mRNA flu shot; virtue signaling with no teeth.────────────────────────────────────────[01:19:56]Dr. Shiva Won a TRO Against Massachusetts Officials for Government-Directed Twitter Censorship in 2020A federal judge barred the state from silencing Dr. Shiva — before Musk, before Twitter Files; Tucker Carlson and Glenn Greenwald refused to cover it.────────────────────────────────────────[01:25:24]Dr. Shiva Discovered the Weighted Race Feature in Election Machines — Trump Made Half a Billion Off That WorkThe feature multiplies one candidate's votes by a scalar; Shiva ran 3,000 audits; Lindell, Trump, and others hijacked the findings and monetized them.────────────────────────────────────────[01:30:32]48% of Americans Are Independent — Tucker Carlson and Andrew Yang Are There to Capture That Energy for the Swarm26% Democrat, 26% Republican, 48% independent nationally; the establishment creates fake independent movements to absorb people breaking from both parties.────────────────────────────────────────[01:36:45]Alex Jones Makes the Truth Unbelievable — Standard CIA TechniqueGives people the tagline without specifics so it sounds like nonsense; when a scientist raises the same issue it has to fight the parody Jones created.────────────────────────────────────────[01:38:24]Dr. Shiva Invited to PBS Senate Debate — Must Raise $250K by September 1stCollected 10,000 certified signatures; threshold added late; 60-70% there; shiva4senate.com/donate.────────────────────────────────────────[02:14:35]Zionism Is a Political Ideology Not a Religion — Like Brahminism It Justifies a Few Ruling Over the ManyFounded by an atheist; wraps politics in religious framing; AIPAC translates that into US policy; Jewish and Zionist are not the same. ──────────────────────────────────────── The Tennessee Farm mentioned in today's program can be seen at: https://www.zillow.com/homedetails/059-05700-Spring-Creek-Rd-Dandridge-TN-37725/439315766_zpid/For information email Roger at FiveRiversLand@ProtonMail.comMoney should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
────────────────────────────────────────[00:02:07]Partisan Split Attempt on Flock and Data Centers — Don't Abandon This Bipartisan Issue to the LeftNew York Sun calls it a leftist crusade; Politico frames it as a radical Democrat movement; if you oppose these because Democrats oppose them, you are serving the surveillance state.────────────────────────────────────────[00:22:37]Tyler Hudson Essay: "I Cannot Remember a Single Child Who Couldn't Speak" — Now It's One in 20 BoysA 22-year autism dad documents childhood in the 1970s; nobody he asks remembers a single nonverbal child; autism was one in 10,000 in 1983, now one in 20 among boys.────────────────────────────────────────[00:32:21]New Cholesterol Guidelines Would Make 100 Million Americans Patients — Disease Creation for a Drug MarketAHA lowered the LDL threshold to 100; a third of Americans now technically diseased; new drugs are ready; purpose is to create lifelong customers.────────────────────────────────────────[00:34:25]Trump's Childhood Vaccine Executive Order Is a Head Fake — States Set the Schedule, Not the PresidentHe signed an order to limit vaccines and split the MMR; states control the schedule; FDA just approved a new mRNA flu shot; virtue signaling with no teeth.────────────────────────────────────────[01:19:56]Dr. Shiva Won a TRO Against Massachusetts Officials for Government-Directed Twitter Censorship in 2020A federal judge barred the state from silencing Dr. Shiva — before Musk, before Twitter Files; Tucker Carlson and Glenn Greenwald refused to cover it.────────────────────────────────────────[01:25:24]Dr. Shiva Discovered the Weighted Race Feature in Election Machines — Trump Made Half a Billion Off That WorkThe feature multiplies one candidate's votes by a scalar; Shiva ran 3,000 audits; Lindell, Trump, and others hijacked the findings and monetized them.────────────────────────────────────────[01:30:32]48% of Americans Are Independent — Tucker Carlson and Andrew Yang Are There to Capture That Energy for the Swarm26% Democrat, 26% Republican, 48% independent nationally; the establishment creates fake independent movements to absorb people breaking from both parties.────────────────────────────────────────[01:36:45]Alex Jones Makes the Truth Unbelievable — Standard CIA TechniqueGives people the tagline without specifics so it sounds like nonsense; when a scientist raises the same issue it has to fight the parody Jones created.────────────────────────────────────────[01:38:24]Dr. Shiva Invited to PBS Senate Debate — Must Raise $250K by September 1stCollected 10,000 certified signatures; threshold added late; 60-70% there; shiva4senate.com/donate.────────────────────────────────────────[02:14:35]Zionism Is a Political Ideology Not a Religion — Like Brahminism It Justifies a Few Ruling Over the ManyFounded by an atheist; wraps politics in religious framing; AIPAC translates that into US policy; Jewish and Zionist are not the same. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
Why do so many companies struggle with cash flow at the exact moment they have their biggest opportunity in front of them? Today we're talking about the hidden financial challenges of growth, how businesses can prepare for larger opportunities, and why access to the right capital strategy can determine whether a company scales or stalls. Our guest today is Eric Rabinovich, Managing Director of X-Caliber GovCon Capital. Eric brings a rare perspective to this conversation, having worked as a government contractor, served as a federal contracting officer with the FDA, and now helping businesses access the capital they need to execute on major contracts. During the show we discuss: Why landing a major contract can create a cash-flow crisis even when it's one of the biggest growth opportunities for a business. How to bridge the award-to-payment gap when payroll, vendors, materials and other expenses have to be paid before the customer pays you. How contract-backed working capital works, including how lenders can evaluate unbilled obligated dollars to determine available capital. Why cash flow and profitability are two different conversations and why a profitable business can still run into serious financial trouble. Why waiting until you need capital can dramatically limit your options, and how proactive capital planning can put you in a stronger position. How to prepare your business for financing by maintaining accurate, reliable books and understanding your P&L and financial position. How to compare different financing options, including traditional bank lines of credit, invoice factoring, asset-based lending and contract-based working capital. How to choose capital based on your specific situation, rather than assuming one financing product is automatically the best option. Resources: https://x-calibercap.com/x-caliber-govcon-capital/
Low Value Mail is a live call-in show discussing current events, politics, conspiracies and much more.Every Monday night at 7pm ETSupport The Show:
Skin cancer is the most common cancer in America, yet millions of people never receive the annual skin exam doctors recommend. So what if your primary care physician could detect suspicious moles in seconds using AI?In this episode of the Miami Tech Pod, Maria sits down with Cody Simmons, Co-Founder and CEO of DermaSensor, the company behind America's first FDA-authorized, AI-powered skin cancer detection device.Cody shares the incredible eight-year journey from research project to commercialization — including miniaturizing a 30-pound laboratory machine into a handheld device, navigating the tough FDA approval process, raising venture capital, and building one of Miami's most promising medical technology companies.They also discuss:How DermaSensor works (and why it isn't just taking photos)Why primary care doctors miss up to half of melanomasThe realities of building a healthcare startup versus softwareThe future of AI in preventative healthcareMiami's evolution into a serious healthcare and technology hub
Devin: What is your superpower?Emily: So I think— I, I don't— it's hard for me to boil it down to just one, but I would simply say my superpower is really rooted in connecting dots. And so seeing things that others may not see because I'm able to put the dots together.Food as medicine can move from a hopeful idea to a scalable health care solution when the people closest to the problem build the system.That is the lesson I heard from Emily Brown, founder of Attane Health and now Chief Healthcare Officer at Sifter Solutions after Attane's acquisition. Emily's work began not with a business plan but with her daughter's diagnosis and a family grocery budget that suddenly could not keep up.“It all started with lived experience, my family's own personal experience with food insecurity and just the need to have specific foods to support my daughter's health,” Emily told me. “We were on WIC, SNAP. I'm actually a former Medicaid recipient.”That experience revealed a gap in health care that millions of families know too well. Doctors can diagnose food-related conditions but families are often left alone to figure out how to pay for and prepare the foods that could help them heal.Emily first responded by founding a nonprofit that helped get special dietary foods into food banks and pantries. Under her leadership, the organization launched one of the first food prescription programs in Kansas, serving clients who had prescription diet orders from physicians.Over time, Emily saw that charity alone could not solve the problem at national scale. Health care needed the tools, data and infrastructure to make food and nutrition care part of routine delivery.“I knew that technology was gonna be really important to scaling our work,” she said. “So I left the nonprofit, started what became Attane, really to develop the technology and the infrastructure to do food and nutrition care at scale.”Attane Health now works as the health care arm of Sifter Solutions, partnering with health plans, pharmacy benefits and health systems to expand access to nutrient-dense foods, education and measurable outcomes. Emily pointed to high-risk maternal health as one powerful example, where better nutrition can support mothers facing gestational diabetes or preeclampsia while helping reduce risks for babies.Her message is practical and hopeful. Food is not a side issue in health care. For millions of people living with chronic conditions, food is part of the standard of care. Emily is helping build the bridge so patients can actually access it.tl;dr:This episode shows how lived experience can spark scalable health care innovation.Emily Brown built Attane Health to make food and nutrition care accessible.Attane Health now grows through Sifter Solutions after a strategic acquisition.Emily explains why storytelling helps turn hidden health challenges into action.This article highlights practical ways to develop the superpower of connecting dots.How to Develop Connecting Dots As a SuperpowerEmily describes her superpower as “connecting dots” and “being able to tell that story.” She sees things others may miss because she can “put the dots together,” then frame the insight in a way that helps others act. She said, “The power of storytelling is really significant because we learn through stories, we connect through story.” That combination has helped her move from being a mother on Medicaid facing food insecurity to becoming a venture-backed founder building solutions for families like hers.Emily's superpower became visible when her daughter received a diagnosis that required a gluten-free diet. Overnight, Emily looked in her pantry and realized many of the foods her family relied on were no longer safe. Her grocery budget quadrupled while her resources shrank. Instead of accepting a system that paid only for clinic care, she began identifying every point of friction. That led her to start a nonprofit, create food prescription programs, advocate before federal agencies and eventually build Attane Health to integrate food and nutrition care into health care at scale.Frame your challenges as opportunities for growth, connection and innovation.Ask what is missing from the data before assuming the data tells the whole story.Look for the friction points hiding in plain sight and treat them as places to build solutions.Bring others with you by using stories from data, patients and partners.Be patient when building disruptive solutions because meaningful change often takes time.By following Emily's example and advice, you can make connecting dots a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileEmily Brown (she/her):Founder of Attane Health, Chief Healthcare Officer at Sifter Solutions, Attane Health, Now a Sifter Solutions CompanyAbout Attane Health: To improve health through food and nutrition care by providing access to health foods, education, and actionable data.Website: attane-health.com, siftersolutions.comCompany Facebook Page: facebook.com/attanehealthBiographical Information: Emily is the Co-founder of Attane Health and Chief Healthcare Officer of Sifter Solutions, a digital health company in the “food is medicine” space. Rooted in lived experience, Emily leads a passionate team dedicated to changing health outcomes through harnessing the healing power of food.After experiencing first-hand, the challenges of managing chronic health conditions with limited resources, Emily founded Food Equality Initiative (FEI). Under her leadership the nonprofit grew to a 7-figure annual budget, supporting patients access to healthy food. Emily is a national patient advocate who has provided both oral and written testimony to the FDA and USDA. A member of the 2025 Child and Adult Core Set Annual Review Workgroup, Emily works to advance health equity in all pursuits.Her research interests include food systems, health disparities, and patient-centered approaches to care. Emily is a published co-author of several peer-reviewed articles with top research institutions in allergic disease. Emily believes in the power of patients and data to achieve greater health outcomes.Personal X/Twitter: @emilybrownspeak Personal Facebook Profile: facebook.com/emily.brown.37853Instagram: @emilybrownspeaksSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include PurposeBuilt100™ Winners and supercrowd.tv. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Eric Coury, Arthia AI | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Ken Steele, Rotarian | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Mike Babbit | Coledger Solutions | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Join the SuperCrowd Impact League! You can be recognized for making impact investments via Reg CF. See how your activity compares to your peers. It's free. Win valuable prizes. Start now!SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on August 11th at 8:00 PM ET/5:00 PM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour, August 19, 2026, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “How to Make Money As an Impact Investor Starting with $10.” Drawing on his experience as a former investment banker, impact investor, and crowdfunding expert, Devin will demonstrate how anyone can begin building wealth while investing in companies that create positive social and environmental impact—even with as little as $10. In this session, he'll explore how impact crowdfunding has opened investment opportunities to everyday investors, explain how to identify promising mission-driven companies, and share practical strategies for building a diversified portfolio over time. Attendees will learn how to get started with limited capital, manage risk, evaluate investment opportunities, and avoid common mistakes new investors make. Whether you're completely new to investing or looking for an affordable way to expand your impact investing portfolio, this SuperCrowdHour will provide actionable insights to help you invest with purpose, build long-term wealth, and make a meaningful difference. Register now!SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Register Now! Join Investors Circle and DAF Commons on August 19, 2026, from 12:00–1:30 PM ET for an insightful conversation on how Donor Advised Funds (DAFs) can become a powerful engine for impact investing. Hear from leaders at ImpactAssets, Impact Charitable, and RSF – Regenerative Social Finance as they explore ways to put charitable capital to work creating measurable impact today. Learn about emerging opportunities for DAF holders to participate in pooled impact investments and climate-focused funding initiatives.Register Now! October 20th and 21st will be the Crowdfunding Professional Association Regulated Investment Crowdfunding Summit for 2026. This is the event of the year for everyone in the crowdfunding ecosystem.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We share educational information—not investment advice. Some links may generate compensation. See our full disclosure.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.
Brittney Miller is President of Manchester Farms, America's first quail farm. What started over 40 years ago as a backyard hobby has grown into a nationally recognized, family-owned business that produces more than 80,000 quail weekly, raising them responsibly, without antibiotics or hormones, and shipping premium products to chefs, retailers, and home cooks across the country. Brittney's story is about more than farming: it is about stewardship, innovation, and family values. She combines her passion for sustainable agriculture with modern food safety standards. Her SQF Level 2 certified, HACCP-compliant farm sets the benchmark for quality in specialty poultry. In this episode of Food Safety Matters, we speak with Brittney [28:27] about: The history of Manchester Farms, America's first quail farm, and how the Miller family built a vertically integrated specialty poultry operation How food safety considerations for quail production compare with those for more conventional poultry, including unique challenges and operational considerations What SQF Level 2 certification and a HACCP program look like in practice within a specialty poultry production environment How HACCP guides day-to-day operations, and how it has evolved as production expands and processes change News and Resources News Researchers Propose Listeria Biofilm Colonization Hypothesis to Explain Persistence in Food Processing Plants [7:05] Researchers Identify Plastic Food Contact Material Properties, Background Microbes that Influence Listeria Biofilm Persistence [8:52] Research Collaboration Produces Guidance for Controlling Spore-Forming Bacteria in Plant-Based Beverage Ingredients [17:22] FDA to Centralize Administrative Functions, Generalize Inspectors [21:00] We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how stakeholders in the U.S. are responding to the challenge.The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last week.View full story: https://www.biocentury.com/article/660433#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning00:00- Introduction01:15 - Academic Centers10:42 - Policy Picture15:48 - Grand Rounds Europe Highlights18:01 - Federated Learning28:15 - NASDAQ IPOsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Send us Fan MailA 27 year old woman went to a longevity clinic in the Bronx for an NAD IV drip. Minutes later she was in cardiac arrest. She died a few hours after that. The person who ran the clinic held a medical license from the Dominican Republic, not the United States.Dr. Kevin White talks with Dr. Matt Kaeberlein, a researcher who studies why and how we age, about what that story actually tells us. His answer isn't really about NAD. It's about certainty. Kaeberlein has never seen evidence that NAD infusions help anyone, and the field's founding claim, that NAD declines with age and needs replacing, is now being questioned by the same scientists who study it. Clinics keep selling it with total confidence anyway.That same pattern shows up everywhere they go in this conversation. Kaeberlein now chairs Montana's expanded Right To Try review board, which lets biotech companies test experimental therapies on real patients once they clear a phase one safety bar, outside the usual FDA process. He explains why that could produce safety data the field has never had, and why he'd reject any therapy pitched without a real scientific rationale behind it, no matter how confidently it's sold."You don't want to listen to the people who are telling you with a hundred percent certainty, do this. And by the way, you know, buy my longevity latte." — Matt KaeberleinThey also compare LinAge2, a biological age calculator built from standard bloodwork with decades of mortality data behind it, to the consumer epigenetic age tests sold directly to the public. Kaeberlein's problem with the popular tests has nothing to do with the underlying science. It's that nobody selling them will publish the error bars, so a 20 year gap on your result could mean everything or nothing. You can't run statistics on a number you're not allowed to check.Along the way they cover why rapamycin, the drug most associated with Kaeberlein's name, might not even be his top pick anymore. A company spun out of his lab, Aura Biomedical, has found longevity molecules that also protect against radiation damage. And a new epigenetic instability test from Irena Conboy's company, Generation Lab, measures something closer to biological chaos than biological age.Follow The Daily Apple and leave a review to help more people find the show. Instagram: @KevinWhiteMDYouTube: @KevinWhiteMD Prime Health Associates
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.
Your AirPods Pro can run a real hearing test. FDA approved and free. Plus, AI generated country band, Breaking Rust, just hit #1 on Billboard's digital sales chart. We talk about what's next for chatbot music. Learn more about your ad choices. Visit megaphone.fm/adchoices
We break down T1's shocking call to bench Oner for rookie Jungler Painter in an LCK showdown against Hanwha Life Esports. LFN Premium: Submit topics through private Discord channels, go ad-free across all 16 LFN shows on every podcast platform, and help keep LFN free. Sign up at https://www.lastfreenation.com Hims: Weight Loss by Hims offers access to FDA-approved GLP-1 options like the Wegovy pill and pen to help you lose weight and keep it off, no insurance necessary. Visit https://hims.com/powerspike DripDrop: Doctor-developed, science-based fast hydration with three times the electrolytes of leading sports drinks, trusted by pro teams and perfect for staying ahead all summer long. Use code LFN at https://dripdrop.com for 20% off your first order Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
All Links Here: https://hunterwilliamshealth.com/linksMelanotan 1 and Melanotan 2 are the two peptides people ask me about every summer. So I put together the full masterclass on both.I combined them because you cannot really talk about one without the other. They came out of the same research program at the University of Arizona. But they hit different receptors, and that changes everything about how you use them.We get into how the melanocortin system works and why sunlight is still required. I walk through the eumelanin shift, which is the pigment that actually protects you. Melanotan 1 is FDA approved for a rare light sensitivity condition. Melanotan 2 has three small studies from the 90s and a lot of gray market use.I cover my dosing tiers, dosing by skin type, cycling patterns, and how to time a cycle around a beach trip or a wedding. I also cover what to stack it with and what to never run alongside. Then the side effects nobody warns you about. Nausea, flushing, darkening moles, and priapism are all real.I talk honestly about the skin cancer question. Nobody knows for sure, and I say that.My verdict is at the end. For most people it is not the one they expect.
A healthy 27-year-old walked into a Bronx wellness center for an NAD+ "longevity infusion" — and was dead within the hour. The man holding the needle wasn't licensed to practice medicine anywhere in the US. Robert Lufkin MD breaks down the Elizabeth Baron case: what actually happened, what NAD+ can and can't do based on the real evidence, why the billion-dollar med spa industry operates like the Wild West, and the three-license checklist that can protect you before anyone puts a needle in your arm.Chapters:00:00 — Introduction: Death After an Anti-Aging IV Drip00:44 — What Happened in the Bronx: The Elizabeth Baron Case01:58 — What's Actually in the Bag: NAD+ Explained02:56 — No Randomized Trial Evidence for IV NAD+03:38 — The Wild West: Inside the Unregulated Med Spa Boom04:02 — A Pattern of Med Spa Deaths and Injuries04:54 — The Three Licenses: Person, Building, Bottle06:19 — The Honest Caveat: Cause of Death Still Pending07:17 — The Takeaway: Fundamentals Beat the DripKey takeaways:NAD+ is real biology — a coenzyme central to energy production and DNA repair — but no randomized trial has ever shown an IV NAD+ drip slows aging in humans.IV NAD+ is legal yet not FDA approved for any specific application, and the marketing has sprinted far ahead of the evidence.An IV bypasses every natural checkpoint in your body. Treat it like surgery on your blood.Before any injection or infusion, verify three licenses: the person, the building, and the bottle. If a clinic can't answer instantly, walk out.The fundamentals that actually move healthspan — muscle, metabolic health, sleep, blood pressure, blood sugar — cost almost nothing and have mountains of evidence.Sources & reporting:NY Daily News — Bronx clinic death and arrestNY Post — arraignment coverageArina Cadariu MD, MPH — "Nobody Is Counting"NY Post — inside the unregulated med spa industryNewser — case roundupCBS News New York — the three licenses
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.
In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL).After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA approved CAR T product since 2017, their discussion explored the following:Review of real-world practice and outcomes in ALLPediatric practical challenges including logistics, leukapheresis, and lymphodepletion chemotherapyStrategies for managing cell therapy toxicities in pediatricpatientsConsiderations for survivorship and long-term toxicitiesGaps in pediatric care and future directionsListen below or via your favorite podcast platform.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape marked by remarkable scientific breakthroughs, strategic alliances, and regulatory milestones that are shaping the future of healthcare. Novo Nordisk is making waves with its new partnership with Amazon Web Services, utilizing artificial intelligence to accelerate drug discovery for chronic diseases. By integrating cloud computing and machine learning models, this collaboration highlights the increasing role of digital transformation in drug development. Novo Nordisk's commitment to innovation is further underscored by the launch of a new London Innovation Hub, enhancing research capabilities in the UK and demonstrating how technology can streamline the development of novel therapeutics. In clinical trial news, Silence Therapeutics has achieved a significant milestone with its investigational therapy Divesiran. This small interfering RNA therapeutic met primary endpoints in a Phase 2 trial for polycythemia vera, highlighting the potential of RNA-based therapies in treating complex blood disorders. Meanwhile, AbCellera's monoclonal antibody therapy ABCL635 has shown promising Phase 2 data for alleviating menopause-related hot flashes, surpassing existing treatments and underscoring the potential of targeted biologics in women's health. Regulatory achievements are further advancing personalized medicine. LabCorp received FDA approval for its PGDx elio tissue complete CDx companion diagnostic for BRAF-mutant advanced melanoma. This tool is pivotal for identifying patients who could benefit from targeted therapies, enhancing precision medicine approaches in cancer treatment. Similarly, AstraZeneca's Calquence and Enhertu have received notable endorsements, reinforcing the critical role of regulatory bodies in facilitating access to innovative treatments. The industry's business landscape is vibrant with strategic partnerships and acquisitions aimed at advancing therapeutic pipelines. Sobi's $580 million deal with Innate Pharma to advance lacutamab through Phase III lymphoma trials underscores how combining expertise can accelerate drug development and commercialization efforts. Financially, companies like Denali Therapeutics are surpassing revenue expectations with products like their enzyme replacement therapy Avlayah for Hunter syndrome, while fundraising activities are empowering biopharmaceutical companies to drive forward pain and oncology initiatives. Despite these advances, challenges persist. Sionna Therapeutics' recent clinical setback in cystic fibrosis reinforces Vertex Pharmaceuticals' dominance in CFTR modulator therapies. Additionally, Tenax Therapeutics encountered disappointment with TNX-103 failing to meet primary endpoints in a Phase 3 trial for pulmonary hypertension associated with heart failure. Manufacturing capabilities are also a focal point as Bristol Myers Squibb plans a substantial investment in Houston, reflecting an industry trend towards expanding infrastructure to meet demand and ensure supply chain resilience. However, compliance remains critical, as seen with Scholar Rock's decision to drop Novo Nordisk's Catalent facility following an FDA inspection. In contrast to setbacks, some companies are achieving breakthroughs. Jazz Pharmaceuticals' acquisition of Actio Biosciences aims to enhance their epilepsy treatment portfolio by integrating clinical-stage assets into its pipeline—a strategic move reflecting ongoing consolidation within the industry. The promise of genetic-targeted therapies is vividly illustrated by Biogen's ALS treatment Qalsody, marking a major scientific breakthrough as the first FDA-approved drug targeting a genetic cause of ALS. Patients have reported symptom stabilization and improvement—a significant advancement given ALS's progressive nature. Meanwhile, psychedelics are emerging as transformative agents in psychiatric medicine. As traditional medications often fall short, psychedelics offer hope for innovative mental health therapies supported by growing clinical and policy backing. However, navigating regulatory landscapes remains challenging. The FDA's recent actions illustrate ongoing struggles to balance innovation with oversight amidst leadership transitions. Real-world evidence is increasingly influencing regulatory decisions—reshaping how companies approach market access strategies by integrating patient experiences into evidence-based decision-making. In oncology, Replimune's melanoma drug has finally earned FDA approval after previous setbacks—a testament to persistence and the potential impact of innovative cancer therapies on patient outcomes. These developments underscore a dynamic pharmaceutical and biotech industry where breakthrough technologies like genetic-targeted therapies and psychedelics promise transformative impacts on patient care. Yet, they also highlight the complexities of bringing these innovations to market amidst stringent regulatory standards and competitive pressures. As we continue to track these stories, one thing is clear: the relentless pursuit of novel treatments remains at the forefront of advancing global healthcare.Support the show
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.
A bitter feud has erupted between Candace Owens and conservative commentator Andrew Wilson over Owens' claims about Charlie Kirk's assassination, with Wilson publicly offering $300,000 for a debate that Owens has countered with a $500,000 proposal. As Jimmy explains, central to the dispute are leaked private messages from Kirk expressing frustration with pro-Israel donors, which Owens released, while Wilson argues she has presented no evidence for her allegations against Israel, TPUSA, and Erika Kirk's potential involvement. Wilson has also faced backlash for his debate tactics after he was caught on video contradicting himself about what the leaked texts actually said. Even Joe Rogan pointed out to Wilson that Erika Kirk's behavior since her husband's death has been "insane." Both Owens and Wilson are currently negotiating the debate's location and terms, with no formal date yet set. Plus segments on Tucker Carlson, Marjorie Taylor Greene, Thomas Massie and others possibly forming a new political party and the FDA's approval of a new mRNA flu vaccine. Also featuring Stef Zamorano, Kurt Metzger and Dr. Angus Dalgleish!
P.M. Edition for Aug. 10. The FDA has laid out new rules intended to make the food system more transparent, part of an overhaul promised by Health Secretary Robert F. Kennedy Jr. WSJ reporter Liz Essley Whyte discusses how the new rules would work and why guidelines for ultraprocessed foods didn't come today. Plus, as Iran strengthens its demands in negotiations to reopen the Strait of Hormuz, Gulf states have begun accepting a new reality: that Tehran will control the strait for the foreseeable future. We hear from WSJ Middle East correspondent Benoit Faucon about what they are doing about it. And more than 70 people have been killed in a 7.4 magnitude earthquake in Colombia. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
(00:00:00) 228: Foods That Can Kill You; and What You Can't Do About IT! (00:00:11) Welcome to the Itchy and Bitchy Podcast (00:00:42) Doc Itchy Medical Pets Supplements (00:01:02) The Dirty Dozen: Pesticide Contaminated Produce (00:07:07) The Pathogen Problem: Foodborne Illnesses on the Rise (00:15:28) The Controversy: What to Do About Contaminated Food (00:25:56) Practical Steps to Reduce Food Contamination Risk (00:31:32) Closing Remarks and Future Episode Preview (00:31:39) Doc Itchy Medical Pets Supplements (Repeat) Cyclospora and Cyclosporosis is infection tens of thousands of AMERICANS causing some deaths. More and More food pathogens are affecting us through contaminated food items and they are making us sick.Add to that the unavoidable contamination of our food with chemicals and pesticides and we are experience a food crisis.Even if you try to eat "Healthy" food items, these may be inthe "dirty Doozen" most contaminated foods available in stores.The Docs discuss the problem, the pathogens, and the pesticides and how we came to find ourselves in this crappy toxic and dangerous time. The Docs will also discuss - argue over what you can or can't do the avoid or prevent your exposure to the pathogens and poisons on and in your foods.Become a supporter of this podcast: https://www.spreaker.com/podcast/itchy-and-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system. From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too. For chronic illness warriors, self-advocacy seekers: WE OFFER No BS
In this episode, I unpack my pregnancy symptoms and emotions from weeks 28-31 and the whiplash of being so ready to not be pregnant anymore while simultaneously freaking out that there's about to be another human in this house!! I get into nesting in the middle of a house renovation, the Braxton Hicks and charley horses I've been experiencing, and how food noise has crept back in during pregnancy. I also open up about my heightened emotions right now and how toxically I miss the way my body used to look.Key Takeaway / Points:Nesting while renovating: purging, hunting down baby gear, and feeling logistically unprepared for the thirdBraxton Hicks, charley horses, alien-style kicks, and the sounds I now make just getting out of a chairFood noise returning during pregnancy and why it feels different this timeLack of sleep, heightened emotions, and my honest feelings about not finding out the sexSummer FOMO with my boys at the beach while pregnantThis episode is sponsored by Natural Cycles, the company behind the first FDA-cleared, hormone-free, and non-invasive birth control app that helps prevent or plan pregnancy naturally. Use code CAMERON at naturalcycles.app/Cameron for 15% off an annual subscription + a FREE NC° Band. The NC° app is for 18+ and does not protect against STIs. Always read and follow the instructions for use.Visit Quiet Your Mind to shop Quiet Your Mind x WTF Is Happening To My Body edition.Follow me:Instagram: @cameronoaksrogersSubstack: Fill Your CupWebsite: cameronoaksrogers.comTikTok: @cameronoaksrogersYouTube: Cameron Rogers
The latest on the strongest earthquake recorded in Colombia in the last decade. President Donald Trump signed an executive order changing the childhood vaccine schedule. The FDA announced a plan to close loopholes in food additives. Russia's calling today's drone strike by Ukraine the deadliest attack inside the country in more than two years. Plus, the long-awaited trial for the murder of rapper Tupac Shakur kicks off with jury selection. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Peptides are everywhere right now—from social media and podcasts to conversations about weight loss, longevity, energy, and overall wellness. But what exactly are peptides, and how do they work in the body? In this episode of Between Two White Coats, Dr. Michelle Plaster and Nurse Practitioner Amber Foster kick off a three-part series on peptides by breaking down the basics. They explain what peptides are, how they interact with the body, and why they believe they can be a valuable tool in a more root-cause and personalized approach to health and wellness. They also discuss the importance of medical supervision, how to think about FDA approval, the role of reputable compounding pharmacies, why peptides may need to be cycled, and who should—and should not—consider peptide therapy.If you've been hearing about peptides and wondering whether they're safe, effective, or right for you, this episode is a great place to start!Listen in as we take a closer look at the science, safety, and potential of peptides—and why they're becoming such an exciting tool in modern health and wellness. Hosted on Acast. See acast.com/privacy for more information.
What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org
Kathy Wieliczko is a nurse practitioner who learned about hormone replacement therapy from Real Housewives of New Jersey. Not from school, or from her doctor, but from Bravo. Her own GYN told her she'd go up a few dress sizes in menopause and that was just life now. Kathy said absolutely not, blocked every person she knew, started an anonymous Instagram at 52, and turned into the girlfriend we all wish we'd had. (You know, the one who tells you the truth in the back of the Uber at 2 AM.) She gives Meg and Carrie the whole list this week. The alcohol. The Peloton habit that had her cortisol through the roof. Why she quit chasing splat points and started lifting heavy for 30 minutes instead. And then they get into peptides, GLP-1 microdosing, and the sketchy vials people are mixing at their kitchen counter like Walter White. Pull up a chair, sis. This is just girl friends talking, not medical advice. Go see your own provider. Find Kathy Instagram: @midlifeinspo Chapters: 00:00 The tips nobody wants to hear 00:40 Meet Kathy Velichko, aka Midlife Inspo 01:15 Why she blocked everyone she knew 02:10 Learning about HRT from Real Housewives 03:00 The GYN who laughed at her 04:20 Megan's testosterone wake-up call at 31 05:35 A nurse practitioner on the struggle bus 06:10 The training doctors never got 06:55 The 30-year reunion victory lap 07:50 Meeting at a Dallas photo shoot 09:30 Cattywampus lips and a ruined birthday 11:45 Doing your makeup when you can't see 13:20 Top five: alcohol, cardio, weights, protein 16:20 Nurses graze all day: the three meal reset 17:45 Walking, cortisol and quitting Orange Theory 19:15 How a GLP-1 company changed her mind 20:15 Microdosing GLP-1: food noise and labs 21:20 The stigma and the people still denying it 22:30 Peptides 101: copper peptide and NAD 23:45 Gray market vials and the Walter White problem 25:05 Big Pharma, compounding and the FDA fight 27:50 BPC-157, Wolverine and the vial in her fridge 30:15 J.Lo, Gwyneth and what's really going on 31:00 Start with one thing before peptides 32:20 How long until you see results 33:20 From one post at 52 to coaching women 34:45 Where to find Kathy
The USDA reports corn and soybeans continue to mature at faster than the average pace while crop condition remains well below a year ago. House Ag Chair Glenn "GT" Thompson shares his resolve to approve a new farm bill. The FDA proposed a rule to enhance oversight of substances claimed to be "Generally Recognized As Safe".
Subtitle: A Nasal Spray Longevity Screen, Why Less Protein May Age You Better, Cadaver Skin Injectables, Art's Effect on Biological Age, and Which Anti-Aging Interventions Actually Move the Needle Nasal Spray Ingredient Emerges As Unexpected Longevity Candidate In Massive Drug Screen Researchers mapped 2,358 longevity-associated genes across the body's broader protein and signaling networks, then screened 6,442 approved drugs to see which ones nudged those aging pathways in a healthier direction. Oxymetazoline, the active ingredient in nasal sprays like Afrin, was among 21 standout candidates, with a predicted pathway running through the ACKR3 receptor and connecting to major aging proteins including NF-kB, TP53, and AKT1. Host Dave Asprey explains why this computational screen is a promising research lead rather than a protocol, and why chronic use of a vasoconstricting nasal spray carries real risks regardless of what a network analysis suggests. Sources: https://www.inc.com/lucia-auerbach/scientists-screened-6442-drugs-for-longevity-common-nasal-spray-emerged-as-a-surprising-candidate/91381000 https://www.sciencealert.com/medications-already-in-pharmacies-may-slow-aging-and-scientists-are-narrowing-them-down https://pmc.ncbi.nlm.nih.gov/articles/PMC12425021/ ~~ New Review Of 350+ Studies Asks Whether Less Protein Means Longer Life A review spanning more than 350 studies found that protein restriction consistently extended lifespan and improved metabolic health across mice, rats, flies, and fish, with smaller human studies showing improvements in body fat and fasting glucose even when total calorie intake rose. Researchers point to FGF21, a liver hormone that rises under protein or amino acid scarcity and boosts energy expenditure and glucose regulation, as a key mechanism. Host Dave Asprey breaks down why blanket protein advice fails older adults preserving muscle and highly active people just as badly as it fails everyone else, and why matching intake to actual biology beats maximizing protein at every meal. Sources: https://www.medicalnewstoday.com/articles/why-reducing-protein-intake-could-promote-healthy-aging-new-research https://time.com/article/2026/08/03/eat-less-protein-age-better-live-longer/ https://www.sciencedaily.com/releases/2026/08/260801042811.htm https://www.cell.com/cell-reports-blue/fulltext/S2949-8821(26)00079-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC8991228/ https://www.eurekalert.org/news-releases/1137190 ~~ Processed Cadaver Skin Injectable Enters The Anti-Aging Market As Elravie Re2O A new injectable called Elravie Re2O, short for "return to your 20s," is made from donated human skin processed to remove living cells and most genetic material, leaving a collagen-rich extracellular matrix that gets injected into the face and neck as a biological scaffold rather than a simple filler. Human-derived tissue matrices already have a track record in burn and wound care, but this specific product is not yet FDA-approved and lacks comparative trial data against existing fillers. Host Dave Asprey separates legitimate regenerative medicine from a novel cosmetic product still waiting on long-term safety and consistency data. Sources: https://nypost.com/2026/07/21/health/the-hottest-new-anti-aging-treatment-cadaver-skin/ https://www.newsobserver.com/living/article316698211.html https://www.miamiherald.com/living/article316698295.html https://pmc.ncbi.nlm.nih.gov/articles/PMC12985180/ https://laboderm-skin.com/elravie-re2o-application/ ~~ UCL Study Finds Weekly Arts Engagement Tracks With Slower Epigenetic Aging A University College London study of more than 3,500 adults found that people who engaged weekly with arts and culture, including painting, music, museums, and theater, showed a roughly four percent slower pace of aging on the DunedinPACE clock and appeared about one biological year younger on PhenoAge, with the effect holding after adjusting for income, education, smoking, and physical activity. Benefits appeared whether people were actively creating art or simply attending performances and exhibits. Host Dave Asprey argues this expands what counts as a health input beyond molecules and devices, since novelty, meaning, and social connection influence the nervous system too. Sources: https://www.npr.org/2026/05/12/nx-s1-5818172/study-arts-slow-biological-aging https://www.news-medical.net/news/20260511/Regular-arts-engagement-may-help-slow-biological-aging-process.aspx https://studyfinds.com/arts-culture-may-slow-aging/ ~~ Review Of 41 Human Studies Ranks Which Interventions Actually Shift Epigenetic Clocks A review of 41 human studies testing interventions against newer-generation epigenetic clocks found favorable changes for exercise, caloric restriction, omega-3s, plant-rich diets, multivitamins, semaglutide, pitavastatin, and ketamine, while nicotinamide riboside, rapamycin, and senolytics showed no detected clock improvement in the studies reviewed. Semaglutide produced the strongest single result, slowing DunedinPACE by about nine percent in a trial of adults with HIV-associated fat redistribution, though a separate fatty liver study produced mixed outcomes. Host Dave Asprey explains why a strong mechanistic story does not guarantee a moved biomarker, and why clinical outcomes, functional measures, and safety data all matter alongside any single clock reading. Sources: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2026.1836446/full https://pubmed.ncbi.nlm.nih.gov/42294499/ https://www.news-medical.net/news/20260616/Semaglutide-omega-3s-and-diet-shift-epigenetic-aging-clocks-in-human-studies.aspx https://www.nature.com/articles/s41514-026-00383-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC12338914/ https://medicalxpress.com/news/2026-06-popular-glp-drug-biological-aging.html https://www.creativebiomart.net/blog/semaglutide-may-slow-epigenetic-aging-in-humans https://www.aging-us.com/article/202913/text https://superpower.com/guides/can-you-reverse-epigenetic-age https://www.nature.com/articles/d41586-026-01836-7 https://www.businessinsider.com/first-ever-reverse-aging-drug-was-just-injected-into-a-human-2026-6 ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into a computational drug-repurposing screen, the case for eating less protein, a new regenerative injectable made from human tissue, the biological effect of creative engagement, and a data-driven ranking of which longevity interventions actually move epigenetic clocks. Host Dave Asprey connects computational biology, nutrition science, regenerative medicine, and biomarker research into practical frameworks for evaluating what belongs in a real longevity protocol versus what belongs on a watch list. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: oxymetazoline longevity, drug repurposing screen aging, ACKR3 receptor aging pathway, protein restriction longevity, FGF21 hormone aging, low protein diet healthspan, cadaver skin injectable, Elravie Re2O, extracellular matrix regenerative medicine, anti-aging injectable 2026, arts engagement biological age, DunedinPACE epigenetic clock, PhenoAge biological age, epigenetic clock interventions, semaglutide epigenetic aging, rapamycin epigenetic clock, senolytics human trials, biological age testing, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Anti-Aging Drug Screening 01:43 – Protein Restriction & Aging 03:36 – New Skin Injectable 05:23 – Arts & Longevity 07:30 – Biohacking Interventions Reviewed 08:51 – Semaglutide & Aging Clocks 09:29 – Closing Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
The White House responds after reports of significantly depleted U.S. stocks of air defense missiles. Senate Democrats target the Pentagon after it changed how it accounts for casualties in the ongoing war with Iran. And the FDA approves Moderna's new mRNA flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
